Bacteremia is the most frequent infectious complication during neutropenia in patients receiving autologous hematopoietic stem cell transplantation (ASCT). The objective of this study was to analyze the incidence, characteristics, risk factors, and outcome of bacteremia during the early period after ASCT. A total of 720 patients undergoing ASCT in two observational prospective consecutive multicenter studies of the Programa Español para el Tratamiento de las Hemopatías group were analyzed. Bacteremia occurred in 20 % of patients. Coagulase-negative Staphylococcus was the most frequent (66 %) among the gram-positive agents and Escherichia coli (49 %) among the gram-negative agents. Multivariate analysis showed that the length of neutropenia <1 × 109/L (more than 9 days) [relative risk (RR) of 2.6, p < 0.001] was the sole risk factor for overall bacteremia. We identified the length of neutropenia <1 × 109/L (more than 9 days) (RR 4.98, p < 0.001) and the use of prophylactic fluoroquinolones (RR 0.46, p < 0.01) as specific risk factors for gram-negative bacteremia. Risk factors for gram-positive bacteremia were the use of total parenteral nutrition (RR 1.92, p < 0.01) and deep neutropenia (<0.1 × 109/L), with duration over 5 days (RR 1.67, p < 0.027). Bacteremia showed an increased morbidity with no impact on neither overall nor infectious related mortality. The identification of such risk factors may be helpful to implement prophylactic and therapeutic risk-adapted strategies to reduce the incidence of bacteremia in ASCT.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Jantunen E, Itälä M, Lehtinen T et al (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 76:245–250
Weaver CH, Schwartzberg LS, Hainsworth J et al (1997) Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 7:671–678
De la Rubia J, Saavedra S, Sanz GF et al (2001) Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 27(1):21–25
Nosanchuk JD, Sepkowitz KA, Pearse RN et al (1996) Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 18(2):355–359
Gil L, Styczynski J, Komarnicki M (2007) Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 35:421–427
Mossad SB, Longworth DL, Goormastic M et al (1996) Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 18(2):265–271
Salazar R, Solá C, Maroto P et al (1999) Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 23(1):27–33
Kolbe K, Domkin D, Derigs HG et al (1997) Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19(2):143–147
Wimperis JZ, Baglin TP, Marcus RE, Warren RE (1991) An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant 8(5):363–367
Reich G, Mapara MY, Reichardt P et al (2001) Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 27(5):525–529
Puig N, de la Rubia J, Jarque I et al (2007) A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation. Int J Hematol 86(2):186–192
Sanz MA, López J, Lahuerta JJ et al (2002) Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 50(1):79–88
De la Rubia J, Montesinos P, Martino R et al (2009) Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study. Biol Blood Marrow Transplant 15(4):512–516
Pizzo PA, Armstrong D, Bodey G et al (1990) From the immunocompromised host society: the design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 161:397–401
Hughes WT, Pizzo PA, Wade JC et al (1992) Evaluation of New anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 15:S206–S215
Link H, Maschmeyer G, Meyer P et al (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol 69(5):231–243
Mermel LA, Farr BM, Sherertz RJ et al (2001) Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32(9):1249–1272
Dixon WJ, Brown MB, Engelman L, Jeinrich RI (1994) BMDP statistical analysis software. University of California, Berkeley
De Pauw BE, Deresinski SC, Feld R et al (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 120(10):834–844
Freifeld AG, Walsh T, Marshall D et al (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165–176
Klumpp TR, Mangan KF, Goldberg SL et al (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 13:1323–1327
Peters WP, Rosner G, Ross M et al (1993) Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709–1719
Hornedo J, Solá C, Solano C et al (2002) The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 29(9):737–743
Shimazaki C, Oku N, Uchiyama H et al (1994) Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 13(3):271–275
Eleutherakis-Papaiakovou E, Kostis E, Migkou M et al (2010) Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 85:863–867
Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A et al (1999) Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 24(10):1079–1087
Auner HA, Sill HS, Mulabecirovic AM et al (2002) Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 81:374–377
Freifeld AG, Bow EJ, Sepkowitz KA et al (2010) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011(52):427–431
Leibovici L, Paul M, Cullen M et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107:1743–1751
Sheean PM, Freels SA, Helton WS, Braunschweig CA (2006) Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12:656–664, Abstract
Marena C, Zecca M, Carenini ML et al (2001) Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infection Control and Hospital Epidemiol 22:510–517
Scolapio JS, Tarrosa VB, Stoner GL et al (2002) Audit of nutrition support for hematopoietic stem cell transplantation at a single institution. Mayo Clin Proc 77:654–659
Weisdorf S, Hofland C, Sharp HL et al (1984) Total parenteral nutrition in bone marrow transplantation: a clinical evaluation. J Pediatr Gastroenterol Nutr 3(1):95–100
Weisdorf SA, Lysne J, Wind D et al (1987) Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 43(6):833–8
Finney SJ, Zekveld C, Elia A, Evans TW (2003) Glucose control and mortality in critically Ill patients. JAMA 290:2041–2047
Krinsley JS (2003) Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically Ill patients. Mayo Clin Proc 78:1471–1478
Conflict of interest
The authors declare that they have no conflict of interests.
José Luis Piñana and Pau Montesinos contributed equally to this manuscript.
About this article
Cite this article
Piñana, J.L., Montesinos, P., Martino, R. et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 93, 299–307 (2014). https://doi.org/10.1007/s00277-013-1872-4